RNA-seq of cardiomyocytes exposed to glucose deprivation with or without empagliflozin treatment

Glucose-lowering drugs sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of serious heart failure events, regardless of diabetes status, but the underling mechanism of this cardioprotective benefit is unknown. Here, we performed RNA-seq screening in cardiomyocytes to determine the potential cardioprotective mechanism of empagliflozin (EMPA). Examination of control group, GD-treated without EMPA treatment group, GD-treated with EMPA 100μM treatment group, GD-treated with EMPA 200μM treatment group in H9c2 cells by RNA-seq, in triplicate